“Over the past few decades, the rate of active surveillance has been around 10%. Now in recent years, the rate of active surveillance is 55% across the U.S. So times are changing," says Sigrid Carlsson, MD, PhD, MPH, in this interview.
Active surveillance for select men with localized prostate cancer is a safe management strategy at a follow-up of 17 years, researchers from Memorial Sloan Kettering Cancer Center reported.
The risk of metastasis was 1% at 10 years and 5% at 15 years, said first author Sigrid Carlsson, MD, PhD, MPH, at the Society of Urologic Oncology annual meeting in Phoenix. The large-scale study included 2,600 patients with Gleason 6 prostate cancer and about 200 with Gleason 3+4 disease.
In a video interview with Urology Times, Dr. Carlsson discusses additional results of the study, ideal candidates for an active surveillance protocol, patient follow-up, and the growing acceptance of active surveillance as an alternative to definitive treatment.
“Over the past few decades, the rate of active surveillance has been around 10%,” she said. “Now in recent years, the rate of active surveillance is 55% across the U.S. So times are changing.”
Lenvatinib/pembrolizumab compares favorably with frontline standards in renal cell carcinoma
February 2nd 2024“Combination therapy with lenvatinib plus pembrolizumab provides a comparable OS, and a trend of improvement in PFS and response outcomes, compared with most current global SOC therapies for treatment-naïve patients with advanced renal cell carcinoma,” the study authors wrote.
First-line pembrolizumab/lenvatinib shows efficacy for advanced non–clear cell RCC
January 29th 2024“Updated efficacy and safety results continue to support pembrolizumab plus lenvatinib as a first-line treatment option for patients with advanced non–clear cell RCC,” lead study author Martin H. Voss, MD.